Cymabay Therapeutics, Inc.

Cymabay Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for liver and metabolic disease. It seeks to address significant unmet medical needs through its specialized treatment options. Founded in 1991 and headquartered in Newark, US, Cymabay Therapeutics, Inc.

specializes in developing treatments for liver and metabolic diseases. The company has undergone a series of funding rounds, with the most recent being a TRADE SALE in July 2014, raising USD 4,300. 00 mn. The CEO of the company is Sujal Shah.

Cymabay Therapeutics focuses on developing innovative therapeutics for liver diseases. Its offerings include various clinical-stage candidates aimed at addressing unmet needs in metabolic disorders. The company is engaged in advancing its drug candidates through clinical trials to assess their efficacy and safety in treating liver and metabolic diseases. In 2018, Cymabay Therapeutics recorded a revenue of USD 0, with an EBITDA of USD -92,401,000 for the same year.

The revenue model is primarily based on the potential commercialization of its therapeutic products once they reach the market. Cymabay Therapeutics plans to utilize the funding from its most recent deal in July 2014 to accelerate the development of its four clinical-stage candidates. The company aims to launch new products targeting liver and metabolic diseases, with specific timelines for clinical trial phases yet to be disclosed. Additionally, Cymabay is exploring opportunities for expansion into new markets, although specific geographic regions have not been identified in the current strategy.